TERREMOTO
LIVE

Serial Number

97697582

Owner

TERREMOTO BIOSCIENCES, INC.

Attorney

John Paul Oleksiuk

Filing Date

Nov 30, 2022

Add to watchlist:

No watchlists yet
View on USPTO

TERREMOTO Trademark

Serial Number: 97697582

TERREMOTO is a trademark filed by TERREMOTO BIOSCIENCES, INC. on November 30, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

TERREMOTO BIOSCIENCES, INC. (5 trademarks)

230 East Grand Avenue, Suite 200
South San Francisco, CA 94080

Entity Type: 03

Trademark Details

Filing Date

November 30, 2022

Registration Date

Not Registered

Published for Opposition

May 21, 2024

Goods & Services

Drug discovery and development services; computational drug discovery and development services; scientific, medical, biotechnology, biomedical, medicinal chemistry, and pharmaceutical research and development services; scientific and medical testing services in the fields of biotechnology, biomedical, medicinal chemistry, and pharmaceuticals; research, development, discovery and consulting services in the fields of biotechnology, biomedical, medicinal chemistry, and pharmaceuticals; research in the fields of chemistry and medicinal chemistry; medical research; clinical research and development services in the fields of biotechnology, biomedical, medicinal chemistry, and pharmaceuticals; medical and scientific research, namely, conducting and evaluating clinical trials for others; providing information about medical and scientific research; providing scientific information in the fields of medicine, biotechnology, medicinal chemistry, and pharmaceuticals; provision of drug discovery and development information; provision of computational drug discovery information;

Pharmaceuticals for the prevention and treatment of cancer, oncological diseases, disorders and conditions; pharmaceuticals for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; pharmaceutical preparations and substances for the prevention and treatment of cancer, oncological diseases, disorders and conditions; pharmaceutical preparations and substances for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; biopharmaceuticals for the prevention and treatment of cancer, oncological diseases, disorders and conditions; biopharmaceuticals for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; medicines for the prevention and treatment of cancer, oncological diseases, disorders and conditions; medicines for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; drugs for the prevention and treatment of cancer, oncological diseases, disorders and conditions; drugs for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; drug compounds for the prevention and treatment of cancer, oncological diseases, disorders and conditions; drug compounds for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; small molecules for the prevention and treatment of cancer, oncological diseases, disorders and conditions; small molecules for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; therapeutics for the prevention and treatment of cancer, oncological diseases, disorders and conditions; therapeutics for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions;

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 14, 2026 EXRA
SOU EXTENSION 3 GRANTED
Jan 13, 2026 EX3G
SOU EXTENSION 3 FILED
Jan 13, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
Jan 13, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 3, 2025 EXRA
SOU EXTENSION 2 GRANTED
Jul 2, 2025 EX2G
SOU EXTENSION 2 FILED
Jul 2, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 2, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 4, 2025 EXRA
SOU EXTENSION 1 GRANTED
Jan 8, 2025 EX1G
SOU EXTENSION 1 FILED
Jan 8, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 7, 2025 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 6, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 6, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 6, 2024 REAP
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 16, 2024 NOAM
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 3, 2024 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jun 3, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jun 3, 2024 COAR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 21, 2024 NPUB
PUBLISHED FOR OPPOSITION
May 21, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 1, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 17, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 13, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 13, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 13, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Oct 19, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Oct 19, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 16, 2023 GNRN
NON-FINAL ACTION E-MAILED
Sep 16, 2023 GNRT
NON-FINAL ACTION WRITTEN
Sep 16, 2023 CNRT
ASSIGNED TO EXAMINER
Sep 9, 2023 DOCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jan 25, 2023 ASGN
NOTICE OF DESIGN SEARCH CODE E-MAILED
Dec 23, 2022 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 22, 2022 NWOS
NEW APPLICATION ENTERED
Dec 3, 2022 NWAP